Reply
It is an interesting point, but it again boils down to the fact that limitation of intra-aortic balloon pump (IABP) in cardiogenic shock is due to incomplete understanding of pathophysiology of this condition, being different in different etiologies responsible for cardiogenic shock. Since IABP helps mostly "by decreasing the afterload to the heart and increasing the diastolic blood flow in the coronaries," it may be useful in ischemic destabilization but only when delivered quite early. 1 
